Determination of serum BRAK/CXCL14 levels in healthy volunteers

Laboratory Medicine

Volumn 41, Issue 8, 2010, Pages 478-482

  Izukuri, Kazuhito ^a   Ito, Shin ^a   Nozaki, Naohito ^a   Yajima, Nobuyuki ^a   Iwamiya, Mariko ^a   Kawahara, Sachiko ^a   Suzuki, Kenji ^a   Kubota, Eiro ^a   Hata, Ryu Ichiro ^a  

^a KANAGAWA DENTAL COLLEGE   (Japan)

Author keywords

BRAK; Chemokine; CXCL14; Enzyme linked immunosorbent assay (ELISA)

Indexed keywords

CXCL14 CHEMOKINE;

ADULT; AGED; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; NORMAL HUMAN; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE;

EID: 77955744993     PISSN: 00075027     EISSN: 19437730     Source Type: Journal    
DOI: 10.1309/LMQOXCQEF7ZXIIUK     Document Type: Article

References (11)

1. Zlotnik A, Yoshie O, Nomiyama H. The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol. 2006;7:243. (Pubitemid 46995589)
2. Meuter S, Moser B. Constitutive expression of CXCL14 in healthy human and murine epithelial tissues. Cytokine. 2008;44:248-255.
3. Kurth I, Willimann K, Schaerli P, et al. Monocyte selectivity and tissue localization suggests a role for breast and kidney-expressed chemokine (BRAK) in macrophage development. J Exp Med. 2001;194:855-861. (Pubitemid 32983020)
4. Schaerli P, Willimann K, Ebert LM, et al. Cutaneous CXCL14 targets blood precursors to epidermal niches for Langerhans cell differentiation. Immunity. 2005;23:331-342. (Pubitemid 41317799)
5. Starnes T, Rasila KK, Robertson MJ, et al. The chemokine CXCL14 (BRAK) stimulates activated NK cell migration: Implications for the downregulation of CXCL14 in malignancy. Exp Hematol. 2006;34:1101-1105. (Pubitemid 44080391)
6. Nara N, Nakayama Y, Okamoto S, et al. Disruption of CXC motif chemokine ligand-14 in mice ameliorates obesity-induced insulin resistance. J Biol Chem. 2007;282:30794-30803. (Pubitemid 350035195)
7. Shellenberger TD, Wang M, Gujrati M, et al. BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells. Cancer Res. 2004;64:8262-8270. (Pubitemid 39496830)
8. Ozawa S, Kato Y, Komori R, et al. BRAK/CXCL14 expression suppresses tumor growth in vivo in human oral carcinoma cells. Biochem Biophys Res Commun. 2006;348:406-412. (Pubitemid 44218985)
9. Ozawa S, Kato Y, Ito S, et al. Restoration of BRAK / CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma. Cancer Sci. 2009;100:2202-2209.
10. Takahashi M, Takahashi Y, Takahashi K, et al. CXCL14 enhances insulin-dependent glucose uptake in adipocytes and is related to high-fat diet-induced obesity. Biochem Biophys Res Commun. 2007;364:1037-1042. (Pubitemid 350087905)
11. Izukuri K, Suzuki K, Yajima N, et al. Chemokine CXCL14/BRAK transgenic mice suppress growth of carcinoma cell xenografts. Transgenic Res. 2010; in press, Nov 24 [Epub ahead of print].